Sector News

Sean Bohen to leave AstraZeneca as exodus continues

January 15, 2019
Life sciences

After creating two new R&D units and simultaneous commercial units to run alongside them, with a new and controversial scientist taking up the cancer research reins, the changes and departures keep coming from AstraZeneca.

Today, Bloomberg reports that Sean Bohen, M.D., Ph.D., CMO and EVP of global medicines development, is out the door, following closely in the footsteps of Bahija Jallal, Ph.D., former head of its biologics arm MedImmune, now CEO of Immunocore, as well as portfolio strategy chief Mark Mallon.

The R&D and commercial changes announced last week were a reaction to these departures and saw José Baselga, M.D., Ph.D., run its newly formed cancer-focused unit. He had been physician-in-chief at Memorial Sloan-Kettering but was forced out in the fall over allegations he was paid renumeration from biopharmas that were not properly disclosed.

Mene Pangalos, Ph.D., who was previously responsible for the company’s Innovative Medicines and Early Development Biotech Unit, now runs a second, nononcology unit.

Bohen now becomes the latest high-profile executive to leave the company. The British-based pharma confirmed to FierceBiotech that Bohen will be leaving but won’t be going until a successor is found. The former Genentech executive did not say where he would be setting his sights on next, but the company said he was key in the company’s growth, and that he will leave “eventually,” although a direct successor is not yet being sought.

This comes amid a mixed time for AstraZeneca, with its CEO Pascal Soriot also endlessly speculated to be heading for the exit, something however he continuously denies, and a plethora of trial setbacks over the years, with cancer becoming a brighter spot but still being hit by some late-stage failures.

By Ben Adams

Source: Fierce Biotech

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend